Evidence map›Paper›PMID 39721696›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Esophageal Dysfunction in Immune Checkpoint Inhibitor-related Myositis.

Yoya Ono, Kenjiro Kunieda, Tomohisa Ohno, Ichiro Fujishima, Takayoshi Shimohata

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yoya OnoDepartment of Neurology, Gifu University Graduate School of Medicine, Japan.
Kenjiro KuniedaDepartment of Neurology, Gifu University Graduate School of Medicine, Japan.
Tomohisa OhnoDepartment of Dentistry, Hamamatsu City Rehabilitation Hospital, Japan.
Ichiro FujishimaDepartment of Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Japan.
Takayoshi ShimohataDepartment of Neurology, Gifu University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 69-year-old woman with left-sided breast cancer developed elevated creatine kinase levels and muscle weakness in her extremities after treatment with pembrolizumab. The patient was diagnosed with immune checkpoint inhibitor (ICI)-related myositis. Although the patient had no symptoms of dysphagia, we evaluated her swallowing function because esophageal dysfunction is a known complication of idiopathic inflammatory myopathy. A videofluoroscopic swallowing study detected barium residues in the lower esophagus. Furthermore, high-resolution manometry showed impaired upper esophageal sphincter opening and absence of esophageal peristalsis, which improved partially after immunotherapy. These findings suggest that esophageal dysfunction may be an unrecognized complication of ICI-related myositis.

Indexed as

Antibodies, Monoclonal, HumanizedEsophageal DiseasesImmune Checkpoint InhibitorsMyositisAgedBreast NeoplasmsDeglutition DisordersFemaleHumansManometryAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspembrolizumabesophagushigh-resolution manometryimmune checkpoint inhibitorimmune-related adverse eventsmyositis

Identifiers

PMID39721696
PMCPMC12287593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.